
    
      Patients with schizophrenia will be screened then enrolled for one week placebo trial in
      addition to their existing antipsychotic medication. If pill compliance is greater than 80%,
      then they will receive baseline clinical, cognitive, and brain imaging and all clinical
      laboratory examinations and a physical examination, vital signs, and cardiogram. Then
      patients will receive in a randomized double blind trial either DMXB-A-SR (3-2,4
      dimethoxybenzylidene anabaseine sustained release) or placebo comparator in addition to their
      existing antipsychotic medication. After one month patients will receive repeat clinical,
      cognitive, and brain imaging testing and all clinical laboratory examinations and a physical
      examination, vital signs, and cardiogram.
    
  